Innobio 2
Investor profile
Venture capital
Innobio 2 has backed 1 European tech company across 1 funding round in 2023, joining rounds totalling €129M. Most active in Healthtech. Data as of Nov 2026.
Deals
1
distinct rounds
Companies
1
backed
Active span
2023
1 yr
Total round €
€129M
sum of rounds joined
Deals by year
distinct rounds / yearInnobio 2 — deals by year — interactive chart.
Data table
| Innobio 2 — deals by year | |
|---|---|
| 2023 | 1 |
Top sectors
by dealsInnobio 2 — top sectors — interactive chart.
Data table
| Innobio 2 — top sectors | |
|---|---|
| Healthtech | 1 |
Stages
by dealsInnobio 2 — stages — interactive chart.
Data table
| Innobio 2 — stages | |
|---|---|
| Series C | 1 |
Countries
by dealsInnobio 2 — countries — interactive chart.
Data table
| Innobio 2 — countries | |
|---|---|
| France | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- Andera Partners1
- ATEM1
- Crédit Agricole Création1
- CTI Life Sciences1
- EQT Life Sciences1
- Intermediate Capital Group1
- Kurma Partners1
- Mass General Brigham Ventures1
- Novo Holdings1
- OrbiMed1
- Pontifax Funds1
- Relyens Innovation Santé/Turenne Capital1
- Sectoral Asset Management1
- Sofinnova Partners1
- Tekla Capital Management1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Amolyt Pharma | France | 1 | €129M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Amolyt Pharma | Series C | €129M | 2023-01 |